Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eplerenone
Drug ID BADD_D00786
Description Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
Indications and Usage For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
Marketing Status Prescription; Discontinued
ATC Code C03DA04
DrugBank ID DB00700
KEGG ID D01115
MeSH ID D000077545
PubChem ID 443872
TTD Drug ID D0Q4SD
NDC Product Code 51991-877; 69367-307; 71216-3011; 16729-294; 71205-864; 60687-451; 70436-098; 16729-293; 70436-099; 46014-1102; 70966-0033; 16812-001; 0025-1720; 0025-1710; 71216-3010; 71205-863; 66993-343; 42291-454; 59762-1720; 68554-0116; 14501-0007; 42291-455; 59762-1710; 0378-1031; 66993-344; 51991-878; 73309-095; 0185-5368; 0009-5276; 69367-308; 0185-5369; 0378-1030
Synonyms Eplerenone | Eplerenon | Inspra | 9,11-Epoxy-7-(methoxycarbonyl)-3-oxo-17-pregn-4-ene-21,17-carbolactone
Chemical Information
Molecular Formula C24H30O6
CAS Registry Number 107724-20-9
SMILES CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malaise08.01.01.0030.085069%
Menstrual disorder21.01.01.004--Not Available
Muscle spasms15.05.03.0040.034027%
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.0010.034027%
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.008877%
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Polyuria20.02.03.0020.034027%Not Available
Proteinuria20.02.01.011--
Prothrombin level decreased13.01.02.010--Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.0010.008877%Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.0030.051041%Not Available
Renal failure20.01.03.0050.031069%Not Available
Rhabdomyolysis15.05.05.0020.051041%
Seizure17.12.03.0010.034027%
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Sudden death08.04.01.003; 02.03.04.013--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.034027%
Tinnitus17.04.07.004; 04.04.01.002--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages